Skip to the page

Data / Form D filings / 511 Therapeutics, Inc.

511 Therapeutics, Inc.: Form D filings

511 Therapeutics, Inc., a biotechnology company in Cambridge, MA, filed 2 Form D notices with the SEC between 2022 and 2026. The latest, on October 30, 2026, reports $500,000 sold of a $1 million offering to 1 investor.

SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.

Company details from the filing

Address
1770 MASSACHUSETTS AVENUE #511, Cambridge, MA, 02140
Phone
(617) 818-7126
Industry
Biotechnology
Entity type
Corporation
Incorporated in
Delaware
Year incorporated
2022
Revenue range
Decline to Disclose
Exemptions claimed
Rule 506(b)
SEC identifier (CIK)
1946264

Form D filings

FiledTypeOfferingSoldRemainingInvestorsFirst saleFiling
Oct 30, 2026New notice$1,000,000$500,000$500,0001Oct 21, 2026sec.gov
Oct 6, 2022New notice$599,998$49,999$549,9991Sep 23, 2022sec.gov

Executive officers and directors named in the filing

NameRoleNote in the filing
Shuguang ZhangExecutive Officer, Director
Yancen LuDirector
Uwe B. SleytrDirector
Andrew MarshallExecutive Officer, Director

Other biotechnology companies in Massachusetts that filed recently

Every Form D from the week of Oct 26, 2026 · All recent filings in Massachusetts · All recent Biotechnology filings

Read from SEC EDGAR. Amount sold is what 511 Therapeutics, Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.